Reducing the burden of Herpes Zoster in Italy

Francesco Vitale, Michele Conversano, Paolo Bonanni, Marzia Lazzari, Donato Greco, Antonio Ferro, Silvestro Scotti, Elisabetta Franco, Alessandro Rossi, Stefania Maggi, Donato Greco, Giovanni Gabutti, Antonio Volpi

Risultato della ricerca: Article

9 Citazioni (Scopus)

Abstract

Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologicmanifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ isPost-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, andhyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinicalstudies show a reduction of 51% in the incidence of the disease, 61% of itsburden and 67% of PHN in vaccinees. Protection seems to be long lasting andvaccine safety matches registration requirements. Available evidence suggeststhat the costs for QALY (less than € 20 000) and avoided cases is favorable. Due to the heavy burden of disease, it is time to offer this vaccination to elderly population.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaHUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume11
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Entra nei temi di ricerca di 'Reducing the burden of Herpes Zoster in Italy'. Insieme formano una fingerprint unica.

  • Cita questo

    Vitale, F., Conversano, M., Bonanni, P., Lazzari, M., Greco, D., Ferro, A., Scotti, S., Franco, E., Rossi, A., Maggi, S., Greco, D., Gabutti, G., & Volpi, A. (2015). Reducing the burden of Herpes Zoster in Italy. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 11, 1-7.